EUVIMEDEUVIMED entdecken
Open Access

Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review)

Alexandros Velegrakis, Elisavet Kouvidi, Persefoni Fragkiadaki, Stavros Sifakis

International Journal of Molecular Medicine · 09.08.2023 · 52 (4)

DOI: 10.3892/ijmm.2023.5292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 09.08.2023. Verfasst von Alexandros Velegrakis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University Hospital of Heraklion, 71500 Heraklion, Greece. Hauptthemen laut MEDLINE: Pre-Eclampsia. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preeclampsia (PE) is a major complication of pregnancy with an incidence rate of 2‑8% and is a leading cause of maternal mortality and morbidity. The various consequences of severe preeclampsia for the fetus, neonate and child include intrauterine growth retardation (IUGR), fetal hypoxia, oligohydramnios, intrauterine fetal demise, increased perinatal mortality and morbidity, neurodevelopmental disorders and even irreversible brain damage (cerebral palsy). A number of studies have demonstrated that differences in maternal serum concentrations of angiogenic factors between preeclampsia and normotensive pregnancies can be used as biomarkers, either alone or in combination with other markers, to predict the development of PE. The presence in the maternal circulation of two proteins of placental origin, placental growth factor (PlGF) and soluble fms‑like tyrosine kinase 1 (sFlt‑1), has been shown to be of clinical value, as the sFlt‑1/PlGF ratio appears to be the optimal predictive tool for the development of PE. The measurement of their concentration in maternal serum in screening models, serves as predictive marker for the development of PE or IUGR later in gestation. However, further research is required to improve its clinical applicability and provide guidelines for its use worldwide to achieve more consistent clinical management of women with PE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaFemaleHumansInfant, NewbornPregnancyFetal Growth RetardationPlacentaPlacenta Growth Factor

Stichwörter der Autor:innen

IUGRPlGFangiogenic growth factorspreeclampsiapregnancysFlt‑1

Substanzen

Placenta Growth Factor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University Hospital of Heraklion, 71500 Heraklion, Greece.
  • Genesis Genoma Lab, Genetic Diagnosis, Clinical Genetics and Research, 15232 Athens, Greece.
  • Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.
  • Euromedica Mitera Kritis, 71202 Heraklion, Greece.

Zitieren

APA

Velegrakis, A., Kouvidi, E., Fragkiadaki, P., & Sifakis, S. (2023). Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review). International Journal of Molecular Medicine, 52(4). https://doi.org/10.3892/ijmm.2023.5292

Vancouver

Velegrakis A, Kouvidi E, Fragkiadaki P, Sifakis S. Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review). International Journal of Molecular Medicine. 2023;52(4). doi:10.3892/ijmm.2023.5292

BibTeX
@article{Velegrakis2023,
  author = {Velegrakis, Alexandros and Kouvidi, Elisavet and Fragkiadaki, Persefoni and Sifakis, Stavros},
  title = {Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review)},
  journal = {International Journal of Molecular Medicine},
  year = {2023},
  volume = {52},
  number = {4},
  doi = {10.3892/ijmm.2023.5292}
}
Kostenlos starten →